Business Description
Aclaris Therapeutics Inc
NAICS : 541714
SIC : 8731
ISIN : US00461U1051
Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventiveĀ therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 279.59 | |||||
| Equity-to-Asset | 0.8 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.82 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 43.4 | |||||
| 3-Year EBITDA Growth Rate | -14.3 | |||||
| 3-Year EPS without NRI Growth Rate | -10.4 | |||||
| 3-Year FCF Growth Rate | -7.5 | |||||
| 3-Year Book Growth Rate | 38.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 80.68 | |||||
| 9-Day RSI | 69.63 | |||||
| 14-Day RSI | 62.13 | |||||
| 6-1 Month Momentum % | -76.72 | |||||
| 12-1 Month Momentum % | -86.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.16 | |||||
| Quick Ratio | 4.16 | |||||
| Cash Ratio | 3.85 | |||||
| Days Sales Outstanding | 5.24 | |||||
| Days Payable | 195.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.3 | |||||
| Shareholder Yield % | 0.3 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.14 | |||||
| Operating Margin % | -372.22 | |||||
| Net Margin % | -283.15 | |||||
| FCF Margin % | -254.84 | |||||
| ROE % | -50.99 | |||||
| ROA % | -38.95 | |||||
| ROIC % | -157.55 | |||||
| ROC (Joel Greenblatt) % | -7366.31 | |||||
| ROCE % | -57.33 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.94 | |||||
| PB Ratio | 0.61 | |||||
| Price-to-Tangible-Book | 0.62 | |||||
| EV-to-EBIT | 0.22 | |||||
| EV-to-EBITDA | 0.23 | |||||
| EV-to-Revenue | -0.83 | |||||
| EV-to-Forward-Revenue | 31.63 | |||||
| EV-to-FCF | 0.33 | |||||
| Price-to-Net-Current-Asset-Value | 1.09 | |||||
| Price-to-Net-Cash | 1.23 | |||||
| Earnings Yield (Greenblatt) % | 454.55 | |||||
| FCF Yield % | -82.17 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers